Posts tagged with "who"

Ama Lou Debut Album

Today, fast-rising British singer/songwriter/producer Ama Lou makes her major-label debut with a new EP titled Ama, who? Released via Interscope Records, the five-track project showcases the thought-provoking sounds and visuals that have earned her praise from the likes of Drake, in addition to drawing acclaim from such outlets as VOGUE, Complex, The FADER, and Paper. Produced by Ama, along with Che Pope, Frank Dukes, Murda Beatz, Hi-Tek, and Foster, Ama, who? is a collection of songs that sees Ama reflecting on what she’s accomplished so far, and asserting the direction in which she’s headed. It’s another step forward in her artistic world and confirmation of who Ama is as an artist. 

The follow-up to Ama Lou’s critically lauded 2018 debut EP DDD, Ama, who? features her recent single “NORTHSIDE” — a stripped-back and bouncy track that’s amassed over a million streams on Spotify and, close to 2 million views on YouTube. Directed by Ama and shot by her sister and creative visual partner Mahalia John, the video for “NORTHSIDE” features cameos from A$AP Nast, Taco from Odd Future, Fai Khadra, and more of Ama’s west coast friends. Watch the video HERE.

Track list for Ama, who?:
1. Far Out
2. NORTHSIDE
3. We tried, we tried
4. This Town
5. Better 

Originally from North London, Ama Lou is a classically trained musician who got her start playing guitar at the age of 10, began writing her own songs at 11, and took up piano at 14. Now 21, she introduced the world to her dynamic songwriting with two back-to-back, politically charged singles: “Tbc” (an October 2016 release penned in response to the killing of Eric Garner by New York police) and “Not Always” (a layered meditation on gender, released in December 2016). With its sound described by The Guardian as “husky soul, feathery trap and skittering, downcast R&B,” “Tbc” soon caught the attention of Drake, who later named Ama Lou among the artists who inspired the making of his 2018 album Scorpion. 

Arriving in early 2018, DDD was hailed as “brimming with her signature minimalism” by Billboard, who also noted that the EP “blends colorful synths and snappy drums with her powerful voice.” The three-track project was accompanied by a short-film directed by Ama and shot by her sister Mahalia John. The short film starred Ama Lou as a member of a fictional L.A. crime ring.
Shortly after the release of DDD, Ama Lou headed out on tour with fellow British phenom Jorja Smith. In a review of their May 2018 stop at Brooklyn Steel, Billboard stated that Ama Lou’s “sweeping vocals were powerful yet polished and melted seamlessly into her self-produced, atmospheric melodies.”

 
Ama Lou Ama, who? EP
Retail: https://smarturl.it/Amawho  
Amazon: https://smarturl.it/Amawho/amazonunlimited  
Apple Music: https://smarturl.it/Amawho/applemusic
Google Play: https://smarturl.it/Amawho/googleplay  
iTunes: https://smarturl.it/Amawho/itunes
Pandora: https://smarturl.it/Amawho/pandora
Spotify: https://smarturl.it/Amawho/spotify
YouTube Music: https://smarturl.it/Amawho/youtubemusic 
 
For more information on Ama Lou:
https://www.instagram.com/amaloumusic/
https://www.facebook.com/amaloumusic/
https://soundcloud.com/amaloumusic

Cure for Cancer in Israel

Cancer Researchers in Israel Believe They Will Have A Cure For Cancer In 1 Year

Promising Research with Multi-Agent Toxins

According to the WHO/International Agency for Research on Cancer, 18.1 million cancer cases are diagnosed worldwide each year. Cancer is now the second leading cause of death behind cardiovascular diseases. It is imperative now, more than ever, that we continue to seek new methods to treat this devastating illness.

Recently, Accelerated Evolution Biotechnologies did an interview where stated they believe that they will “offer in a year’s time a complete cure for cancer”. Although it grabs headlines, that is a momentous statement to make. Let’s dig a little deeper into the work that they are currently doing. The premise behind their treatment involves using a multi-agent target toxin treatment to treat cancer. In the past, this type of therapy targeted toxin treatment has involved the introduction of DNA coding for a protein (can be an antibody) into a bacteriophage – which is a virus that infects bacteria. These proteins can then be displayed on the surface of the virus and interact with its surroundings.
The company’s therapy involves a similar phenomenon, but with the use of peptides instead of proteins. Peptides consist of two or more amino acids linked together in a chain. They are smaller than proteins, can serve biological functions, and in many ways are less expensive to reproduce.

Most cancer therapies aim at attacking a target in a cell, on the surface of a particular cell, or in one of its internal pathways.

However, a mutation in one of these targets can make the therapy ineffective. What is being done here, with multi-target toxin therapy, is that several peptides of the cancer cell are being targeted with a peptide toxin to avoid mutations rendering a therapy ineffective. The more targets used, the less likely that a series of mutations will occur simultaneously that will make the therapy ineffective. This will help in not allowing the cancer cell to evade the treatment and continue to replicate, even with some mutations occurring.

This may have the ability to reduce side effects as well, given that the peptides will aim to attack specific targets on the cancer cells that are typically not overexpressed in other healthy cells. In addition, since the peptides are small (the ones they have developed are about 12 amino acids long) and lack a rigid structure, it allows them access to regions of the cell that may be blocked if a larger protein was used.

Overall, they are using a “combination modality” in a very specific manner for an attack of each cancer cell in this therapy. Combinational therapy has been successful before with cancer, HIV, and autoimmune disease among others. The goal of the company is to eventually personalize this to each patient by having a biopsy sent and analyzed for the receptors that it over expresses. The patient would then be administered an individualized concoction developed to treat the disease.

This is exciting and has potential, but more data needs to be presented. Thus far they have concluded mice experimentation and found inhibited human cancer cell growth that did not affect healthy mice cells. They are currently working on beginning a round of clinical trials, which many people will be eager to see the conclusions. Recently, Accelerated Evolution Biotechnologies has been writing patents on a variety of different specific peptides. While their work thus far is enthusing and making headlines, their claim to “offer in a year’s time a complete cure for cancer” is likely premature. Yet, I don’t know a single person, including myself, who wouldn’t hope for that.

Joshua Mansour, M.D. is a board-certified hematologist and oncologist in Stanford, California.  He is currently doing additional work in the field of Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy.

New AI app reduces back pain by 40%

Boston based digital therapy startup Kaia Health launches a new app that uses AI and patent pending motion tracking technologyto personalize treatment programs tomanage and treat chronic low back pain(LBP) which has been shown in clinical studies to reduce chronic back pain by 40% and could save the US economy billions each year.

Created by Kaia Health the motion tracking technology requires no additional hardware.The app has been registered as a Class 1 medical device with the FDA which allowsusers to self-manage their back pain through physical exercise, behavioural exercise (e.g. relaxation and meditation) and education.

Earlier this year the digital therapy startup launched the Perfect Squat Challenge App, the world’s first Artificial Intelligence-powered motion tracking fitness app that turns a smartphone into a personal trainer. In Q4 2018 the company intends to roll out20 more motion tracking exercises for the app.

According to the World Health Organization (WHO) LBP is the single leading cause of disability worldwide. In fact, according to the American Chiropractic Association(ACA) 31 million Americans experience LBP,and one half of all working Americans admit to having back pain symptoms each year.

The epidemic of prescription opioid overuse and abuse has also led many health groupsincluding the ACA, the American College of Physicians (ACP) and the American Association of Pain Management (AAPM) to reconsider the value of a non-pharmalogicalapproach to common conditions such asLBP.

The ACP, the largest medical specialty society in the world, updated its LBPtreatment guidelines in 2017 to support a conservative approach to care. Published in the Annals of Internal Medicine, and based on a review of randomized controlled trials and observational studies, the ACPguidelines cite heat therapy, massage, acupuncture and spinal manipulation (a centerpiece of chiropractic care) as possible options for non-invasive, non-drug therapies for LBP. The guidelines state that only when such treatments provide little or no relief should patients move on to medicines such as ibuprofen or muscle relaxants, which research indicates have limited pain relief effects. According to the ACP, prescription opioids should be a last resort for those suffering from LBP, as the risk of addiction and overdose may outweigh the benefits.

The Kaia app has been developed by aleading digital therapy company Kaia Health in conjunction with physiotherapists, pain management physicians and clinical psychologists.

The app uses a multidisciplinary digital approach which offers users online video-based learning programmes that covereducation, physiotherapy (includingexercises for the lower back and lateral muscles) and psychological strategies(including mindfulness and muscle relaxation).

The AI tailors treatment programs for each user from over 120 exercises, and motion tracking technology ensures that the exercises are performed correctly using a smartphone, tablet or iPad without the need for additional hardware.

Each session lasts for 15 minutes and can be accessed anywhere 24 hours a day. The app also features a chat function whichconnects users to a physiotherapist or sport scientist for motivation and exercise related questions.

Two clinical trials into the Kaia app show a significant reduction in LBP by 40%, well above the clinical threshold of pain improvement. The second study shows a40% long-term retention of users for aminimum of 6 months.

The Kaia app was developed in Germanywhere it has been downloaded over 100,000 times in its first year. The Kaia app is now being reimbursed for over 20 million patients globally.

Kaia Health is member of the Digital Therapeutics Alliance (DTA), an association of international manufacturers for digital therapeutic products that are evidence-based.

Konstantin Mehl, CEO of Kaia Health says:Opioid addiction and overdose is a huge issue in the US, and is, according to the ACP, a last resort for those suffering from LBP. Their 2017 LBP treatment guidelines support a non-pharmalogical approach to care using non-invasive, non-drug therapies. A holistic, multidisciplinary treatment of LBPhas always been a resource-intense, costlyundertaking which makes it hard forpatients to get access to the therapy.However, with the Kaia app we’re digitising therapy which offers as many patients as possible access to effective treatment ofLBP. This empowers and motivatesindividuals to take control, and self-manage their condition with evidenced-based, non-pharmacological, cost-effective alternatives and this could save the US economy billions each year. The Kaia app, and advances in technology, demonstrates why we need to rethink how we treat diseaseconditions such as LBP, and make digitalself-management a more realistic part of treatment.

The Kaia app is available on iOS and Android, and can be downloaded via GooglePlay and AppStore. The first 7 days of the program are free. To unlock the full functionality the costs are: 3 months: $23.99, 6 months: $64.99 and 12 months: $94.99.

About Kaia Health www.kaia-health.com
Founded in 2016, Kaia Health is a leading digital therapy company that creates evidence-based treatments for a range of disorders including back pain, Parkinson’s disease, osteoarthritis and chronic obstructive pulmonary disease. Kaia Health uses innovative technology including artificial intelligence and apps, and works with experts in each medical field to create an interdisciplinary digital approach. This empowers and motivates individuals to take control and self-manage their condition with effective, non-pharmacological, digital alternatives at low costs.